Emergent BioSolutions has initiated a Phase 1b/2 study (16011) to evaluate TRU-016 in conjunction with rituximab and bendamustine in patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, small lymphocytic lymphoma, follicular lymphoma and marginal zone lymphoma.
Developed in collaboration with Abbott, TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical protein therapeutic in development as a treatment for B-cell malignancies.
Go deeper with GlobalData
The company expects to recruit around 88 subjects in the trials in patients with relapsed indolent B-cell lymphoma and those who have failed prior treatments.
The Phase 1b portion of the study aims to establish the Phase 2 dose of TRU-016 given in combination with rituximab and bendamustine.
However, the Phase 2 portion will be an expansion study of approximately 76 additional patients to examine the safety and efficacy of TRU-016 in combination with 375mg/m² of rituximab and 90mg/m² of bendamustine, versus bendamustine and rituximab.
Emergent Clinical Research vice-president and chief medical officer Scott Stromatt said, “Based on the data, as well as data from our ongoing clinical studies of TRU-016 for chronic lymphocytic leukemia, we believe that TRU-016 in combination with bendamustine and rituximab could produce meaningful results in patients with indolent NHL.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataStudy enrollment is expected to be complete by the end of 2012.
